Drug Profile
Research programme: hedgehog cell-signalling pathway inhibitors - Infinity
Alternative Names: IPI-269609; IPI-609Latest Information Update: 11 Mar 2013
Price :
$50
*
At a glance
- Originator Infinity Pharmaceuticals
- Class Small molecules
- Mechanism of Action Hedgehog cell-signalling pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 11 Mar 2013 Discontinued - Preclinical for Cancer in USA (PO)
- 14 Dec 2010 Infinity Pharmaceuticals and Mundipharma expand their strategic alliance agreement
- 04 Nov 2010 Infinity Pharmaceuticals receives three grants under the US Government's Qualifying Therapeutic Discovery Project Programme to advance its three research programmes, including hedgehog pathway inhibitors